Pharmakon1600-01505386

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Pharmakon1600-01505386
• 英文别名: (1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
• 化学式: C₂₇H₃₀F₆N₂O₂
• 分子量: 528.5
• InChiKey: JWJOTENAMICLJG-JLAOSSPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  37
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Active agent delivery systems and methods for protecting and administering active agents
  申请人：Mickle Travis

  公开号：US20070232529A1

  公开（公告）日：2007-10-04

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸（作为单个氨基酸或肽）与活性物质共价连接的组合物以及用于给予共轭活性物质组合物的方法。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090253792A1

  公开（公告）日：2009-10-08

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸（作为单个氨基酸或肽）与活性剂共价连接的组合物以及给予共轭活性剂组合物的方法。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090306228A1

  公开（公告）日：2009-12-10

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽，与活性剂共价结合的组合物以及用于给予共轭活性剂组合物的方法。
• METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION
  申请人：Meehan Alan

  公开号：US20110092470A1

  公开（公告）日：2011-04-21

  A method of treating male sexual dysfunction or erectile dysfunction by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  本文描述了一种通过使用5α还原酶抑制剂和睾酮补充剂来治疗男性性功能障碍或勃起功能障碍的方法。该方法还涉及使用5α还原酶抑制剂和睾酮补充剂与其他用于治疗勃起功能障碍的药物一起使用，包括PDE V抑制剂；AGE（高级糖基化终产物）破坏剂；α1受体阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑色素细胞激素激动剂；催产素激动剂；前列腺素；自由基清除剂；旋转酶抑制剂；aviptadil；硝酸甘油；以及GPCR激动剂，用于治疗男性性功能障碍或勃起功能障碍。
• Method of treating men with testosterone supplement and 5alpha reductase inhibitor
  申请人：MERCK SHARP & DOHME (I.A.) CORP.

  公开号：EP2371367A1

  公开（公告）日：2011-10-05

  A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  描述了一种通过服用 5α 还原酶抑制剂和睾酮补充剂来治疗阿尔茨海默病、帕金森病、性功能障碍或男性勃起功能障碍的方法。该方法还涉及将 5α 还原酶抑制化合物和睾酮补充剂与另一种治疗勃起功能障碍的药物一起使用，包括 PDE V 抑制剂；AGE（高级糖化终产物）分解剂；α 1 阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑皮质素激动剂；催产素激动剂；前列腺素；自由基清除剂；腐胺酶抑制剂；阿维他地尔；硝酸甘油；以及治疗男性性功能障碍或勃起功能障碍的GPCR激动剂。